ARCT 021
Alternative Names: ARCT 021; Coronavirus Vaccine - Arcturus TherapeuticsLatest Information Update: 24 Jan 2023
At a glance
- Originator Arcturus Therapeutics
 - Class COVID-19 vaccines; RNA vaccines; Viral vaccines
 - Mechanism of Action Immunostimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity No
 - Available For Licensing Yes - COVID 2019 infections
 
Highest Development Phases
- Discontinued COVID 2019 infections
 
Most Recent Events
- 24 Jan 2023 Discontinued - Phase-II for COVID-2019 infections (In the elderly, Prevention, In adults) in Singapore (IM)
 - 24 Jan 2023 Discontinued - Phase-II for COVID-2019 infections (In the elderly, Prevention, In adults) in USA (IM)
 - 08 Jul 2022 Arcturus Therapeutics terminates its phase IIa trial in COVID-2019 infections (Prevention, In adults, In the elderly) in Singapore and USA due to business reasons (IM) (NCT04728347)